1472– Cyanoacrylate embolisation for the treatment of varicose veins due to chronic venous insufficiency

Page last updated: 29 September 2017

Application Detail

Status

Open

Description of Medical Service

Cyanoacrylate embolisation (CAE) is a minimally invasive, non-thermal, non-tumescent treatment for varicose veins. CAE is designed as a single use therapeutic intervention, delivered as a single course of treatment per affected leg to emobolise the great saphenous vein (GSV) by means of medical adhesive.

Vein occlusion is achieved by using an ultrasound guided disposable catheter positioned in the area of treatment and then a catheter-administered cyanoacrylate adhesive is injected into the vein to achieve closure. A single small bandage is applied to the catheter entry site and venous occlusion is confirmed by duplex ultrasound.

Description of Medical Condition

Chronic venous insufficiency (CVI) is a disorder that impairs blood flow back to the heart from the legs. Pathophysiological abnormalities present in CVI include incompetent venous valves and loss of structural strength in the walls, resulting in increased intravascular pressure into veins that are intended to function as a low pressure system. Increased pressure causes backflow of blood, or venous reflux, resulting in pooling of blood in the legs. These subcutaneous veins commonly occurring in the legs are called varicose veins.

Lower limb varicose veins are a common disease affecting adults. If chronic and untreated, the associated venous insufficiency can progress to significant morbidity including pain, oedema, fatigue and limb swelling, thrombophlebitis, bleeding and skin ulceration.

Reason for Application

New MBS item

Medical Service Type

Therapeutic

Previous Application Number

Not Applicable

Associated Documentation

Application Form

-

Consultation Survey

-

PICO Confirmation

-

Assessment Report

-

Public Summary Document

Public Summary Document (PDF 416 KB)
Public Summary Document (Word 169 KB)

Meetings for this Application

PASC

-

ESC

8 June 2017

MSAC

27 July 2017